Hutchison China MediTech, Ltd.
Hutchison China MediTech, Ltd., known as Chi-Med, is an innovative biopharmaceutical company aiming to become a global leader in the discovery, development and commercialization of targeted therapies and immunotherapies in oncology and immunological diseases.
Chi-Med's Innovation Platform, known as Hutchison MediPharma, has been the main driver of creating and developing its portfolio of drug candidates since 2002. It has about 550 scientists and staff focusing on discovering, developing, and commercializing targeted therapeutics and immunotherapies in oncology and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world.
Chi-Med has also developed a profitable Commercial Platform, which manufactures, markets, and distributes prescription drugs and consumer health products in China.
Location of Key Operations
Pricewaterhousecoopers Zhong Tian LLP
IPO (March 17, 2016)
March 4, 2021: Hutchison China MediTech Ltd. to Host Earnings Call
February 3, 2021: Chi-Med to Announce 2020 Final Results